Illumina forced to pay almost $334M as it loses DNA sequencing patent case
A federal jury in Delaware on Friday ordered Illumina to pay Complete Genomics Inc., a subsidiary of the BGI Group, the world’s largest maker of commercial genetic sequencers, almost $334 million, finding Illumina infringed on two DNA sequencing patents.
The case, began in 2019 when CGI sued the San Diego-based biotech over the patents, alleging that Illumina’s “two-channel” sequencing system and its kits that prepare DNA fragments for sequencing violated CGI’s patent rights.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.